Wednesday, July 8, 2026

pharma · Covid-19 · Chronic Myocardial Ischemia · LSTA

Lisata Therapeutics

Lisata Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920, US HQ
2006 Founded
38 Employees
Public company Type
LSTA · NYSE Ticker
Company details
Status
Public
HQ
110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920, US
Founded
2006
Employees
38
Programs
15
Drugs
13
Patents
1
Intelligence · Clinical Programs

Lisata Therapeutics projects

4 ClinicalTrials.gov programs sponsored by Lisata Therapeutics.

Lisata Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Biological/Vaccine: therapeutic autologous dendritic cells.

    LISATA THERAPEUTICS, INC.

    Kidney Cancer

    phase 1 mab terminated

    1 trial
  2. CEND-1

    LISATA THERAPEUTICS, INC.

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial
  3. CLBS119

    LISATA THERAPEUTICS, INC.

    Covid-19

    phase 1 mab terminated

    1 trial
  4. CLBS201

    LISATA THERAPEUTICS, INC.

    Chronic Kidney Diseases

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Lisata Therapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.